We also divided patients by their International Metastatic RCC Database Consortium (IMDC) risk score and found reduced LAG3 expression in metastases from “Poor” risk group patients, but not patients in the “Favorable” or “Intermediate” risk groups (Figure 3D). This evidence concerns the gene LAG3 and renal cell carcinoma.